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Purpose: The purpose of this study was to examine the efficacy and safety of valproic acid 
(VPA) use in patients with retinitis pigmentosa (RP).
Patients and methods: This was a prospective, interventional, noncomparative case study. 
In total, 29 eyes from 29 patients with RP whose best-corrected visual acuities (BCVAs) in 
logarithm of the minimum angle of resolution (logMAR) ranged from 1.0 to 0.16 with visual 
fields (VFs) of 10° (measured using Goldmann perimeter with I4) were recruited. The patients 
received oral supplementation with 400 mg of VPA daily for 6 months and were followed for 
an additional 6 months. BCVAs, VFs (measured with the Humphrey field analyzer central 
10-2 program), and subjective questionnaires were examined before, during, and after the ces-
sation of VPA supplementation.
Results: The changes in BCVA and VF showed statistically significant differences during the 
internal use of VPA, compared with after cessation (P=0.001). With VPA intake, BCVA in 
logMAR significantly improved from baseline to 6 months (P=0.006). The mean deviation value 
of the VF significantly improved from baseline to 1 month (P=0.001), 3 months (P=0.004), 
and 6 months (P=0.004). These efficacies, however, were reversed to the baseline levels after 
the cessation of VPA intake. There were no significant relations between the mean blood VPA 
concentrations of each patient and the changes in BCVA and VF. During the internal use of 
VPA, 15 of 29 patients answered “easier to see”, whereas blurred vision was registered in 
21 of 29 patients on cessation. No systemic drug-related adverse events were observed.
Conclusion: While in use, oral intake of VPA indicated a short-term benefit to patients with 
RP. It is necessary to examine the effect of a longer VPA supplementation in a controlled 
study design.
Keywords: retinitis pigmentosa, valproic acid, clinical trial, retina
Introduction
Retinitis pigmentosa (RP) is the term used for a group of retinal diseases that are 
characterized by inherited, progressive degeneration of retinal tissue, mainly rod and 
secondarily cone photoreceptors. The prevalence of RP is ~1:4,000 worldwide. The 
clinical features are night blindness and visual field (VF) loss due to loss of rod photo-
receptors. Many patients fall into a classical pattern of difficulties with dark adaptation 
and night blindness and loss of midperipheral vision field. As the disease advances, 
they lose peripheral vision, eventually developing “tunnel vision” with the remain-
ing cone photoreceptors, and finally lose central vision and visual acuities (VAs) as 
these cones secondarily degenerate in the macular region.1,2 Typically, it takes several 
years until the patients lose their central vision; therefore, it is important to protect 
the cone photoreceptors in the macular area for RP patients. Because RP is caused 
by various mutations in any of 45 responsible genes, the processes of degeneration 
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are considered to be not uniform, and no effective treat-
ment other than nutritional supplementation of vitamin A 
currently exists.
Recently, Noorwez et al3 reported that valproic acid 
(VPA) can increase the yield of properly folded RP mutant 
rhodopsins; by using their high-throughput screening method 
involving in silico, cell-based, and in vitro assays, the 
authors were able to identify pharmacological chaperones 
of misfolded rhodopsin. Based on the data, Clemson et al4 
reported in their retrospective study that treatment with VPA 
in patients with RP improved VAs and VFs.
However, there were controversies over that study,5–7 and 
another group, Bhalla et al,8 not only claimed no improve-
ment in VA and VF in their study but also stated that VPA 
may facilitate some adverse side effects. To date, various 
clinical studies have been performed,9,10 but no conclusion 
has been reached regarding the efficacy of using VPA in 
patients with RP.
VPA has been widely used as an antiepileptic drug for 
several decades. The pharmacological basis of the antiepi-
leptic action of VPA has been related to the regulation of 
the glutamate excitatory neurotransmission and/or gamma-
aminobutyric acid (GABA) inhibitory neurotransmission.11 
Recent studies showed that VPA is an effective inhibitor 
of histone deacetylases, the key enzymes for the control 
of histone acetylation state and hence for the epigenetic 
regulation of gene expression. Mainly through inhibition of 
histone deacetylases, VPA induces apoptosis of microglia 
cells12 and activates BDNF promoter.13 Moreover, VPA 
induces neuronal differentiation but suppresses astrocytic 
and oligodendrocytic differentiation of neural stem cells14 
and promotes neurite outgrowth.15
In this prospective study, we examined the efficacy and 
safety of VPA use in Japanese patients with RP.
Patients and methods
Trial registration
This study is registered with the clinical trials registry of 
the Japan Medical Association Center for Clinical Trials, 
number JMA-IIA00053.
ethics
In this prospective, interventional, noncomparative case 
study, the study protocols adhered to the tenets of the 
Declaration of Helsinki. Ethics committee approval was 
granted by the ethics committee at the Institute of Biomedical 
Research and Innovation. Written informed consent was 
obtained from each patient before any study procedures 
were performed. All the patients were seen at the Institute of 
Biomedical Research and Innovation Hospital (Kobe, Japan) 
from December 2010 to January 2013.
patients
The diagnosis of RP was based on the patients’ symptoms 
of night blindness, ring scotoma or concentric constriction 
of VFs, markedly reduced or nonrecordable a- and b-wave 
amplitudes on electroretinogram (ERG) testing, and oph-
thalmoscopic findings (ie, characteristic fundus changes 
in attenuated retinal vessels and bone-spicule-like pigment 
clumping).
The inclusion criteria were the following: 20 years old 
or older, best-corrected visual acuities (BCVAs) of 20/200 
and 20/30, and VFs of 10° measured using Goldmann 
perimeter with isopter I4.
The exclusion criteria were the following: patients with 
retinal diseases other than RP, including retinal degeneration 
secondary to inflammation or infection and retinal vascular 
or macular diseases; cataractous lens gradings of more than 
N1, C2, or P1 according to Lens Opacities Classification 
System III grading; previous intraocular surgery except for 
uncomplicated cataract extraction; women of childbearing 
potential who were pregnant, nursing, or planning a preg-
nancy; presentation of liver disease or a urea cycle disorder; 
patients who had drug hypersensitivity; patients who had 
attempted suicide or had suicidal thoughts with manic depres-
sive illness; and patients who were using contraindication 
medicine.
Study protocols
Prior to treatment at the initial study visit, each patient under-
went ophthalmic examinations, including BCVA measured 
using a Landolt chart, intraocular pressure measurements, 
VF measured with the Humphrey field analyzer (HFA; 
Zeiss-Humphrey Systems, Dublin, CA, USA) 10-2 program, 
slit-lamp biomicroscopy, and dilated indirect fundus 
ophthalmoscopy.
After baseline measurements were obtained, all the 
patients were instructed to receive oral supplementation of 
400 mg (the lowest dosage used for anticonvulsant therapy) 
of VPA (Depakene-R®; Kyowa Hakko Kirin, Tokyo, Japan) 
daily for 6 months. The patients were followed for an addi-
tional 6 months without VPA intake.
The patients returned to our clinic for follow-up visits and 
were asked to report on the development of any subjective 
visual changes as well as any systemic adverse events. 
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Efficacy and safety of valproic acid for retinitis pigmentosa
throughout the entire study at months 1, 3, 6 (end of supple-
mentation), 9, and 12. Blood samples were collected to 
check blood counts, clinical biochemistry, and the blood 
concentration of VPA at months 1, 2, 3, 4, and 6 (end of 
supplementation).
BCVA was converted to the value of logarithm of the 
minimum angle of resolution (logMAR) for all analyses.
VF test results were summarized using the mean deviation 
(MD) value calculated by the HFA provided software. The 
calculation of the MD value involved averaging the differ-
ences between the measured sensitivities and the age-adjusted 
normal sensitivities (total deviations) at each test point.
Although not included as routine tests in our study design, 
microperimetry-1 (MP-1; NIDEK, Gamagori, Japan) or 
multifocal ERG (VERIS; Electro-Diagnostic Imaging, Inc., 
Redwood, CA, USA and LE-4000; Tomey, Nagoya, Japan) 
were also recorded in some patients at pretreatment and at 
6 months or at 6 months and 12 months.
The primary end point of this study was improvement 
in BCVA after the 6 months of treatment with VPA, and 
the secondary end points were VF and the occurrence of 
adverse events.
Determination of sample size
The variance approximation for the estimation of sample 
size was obtained from previous studies that have tested a 
similar hypothesis.4 A sample size calculation was performed 
before the study, assuming a maximum dropout rate of 30%. 
Accordingly, we assumed that at least 30 patients were going 
to fail power of 80% (β-1) to detect a logMAR 0.2 difference 
in VA between patients before and after receiving VPA.
Statistical analysis
All parameters obtained prior to VPA treatment and at 
1 month, 3 months, 6 months, 9 months, and 12 months 
after treatment initiation were compared using the Wilcoxon 
signed-rank test with Bonferroni correction. We utilized a 
Bonferroni adjustment for multiple comparisons, after which 
P-values 0.01 were considered as statistically significant. 
All statistical analyses were performed using the statistical 
analysis software (SPSS Inc., Chicago, IL, USA).
Results
In total, 31 patients with RP were enrolled in this study. Two 
patients were lost to follow-up after the 6 months visit; the 
data for these patients were not included in the analysis. 
Overall, 29 patients (12 males and 17 females) with RP com-
pleted the 12 months study period. The patients’ ages ranged 
from 30 years to 72 years (mean ± SD: 52.5±11.5 years). 
Mendelian inheritance studies disclosed 13 sporadic, eleven 
autosomal recessive, and five autosomal dominant patterns. 
The age, sex, Mendelian inheritance, BCVA, MD value 
of the VF, and mean blood VPA concentration are shown 
in Table 1.
First, we evaluated the changes in the visual func-
tion during the VPA administration period (from baseline 
to 6 months) and the cessation period (from 6 months 
to 12 months). The median changes in the value of log-
MAR BCVA per month were 0.00 (interquartile range 
[IQR], −0.18–0.00) during administration and 0.00 (IQR, 
0.00–0.20) during cessation, which showed statistically 
significant difference (P=0.001; Figure 1A). The median 
changes in the MD value of VF per month were −0.11 dB 
(IQR, −0.18–0.03) during administration and 0.48 dB (IQR, 
−0.17–0.28) during cessation, which also showed statistically 
significant difference (P=0.001; Figure 1B).
Next, we evaluated the shift in VA (logMAR) and VF 
(dB) over time (Figure 2). The median logMAR BCVA 
values were 0.39 (IQR, 0.30–0.69) at baseline, 0.39 (IQR, 
0.30–0.52; P=0.08) at 1 month, 0.39 (IQR, 0.30–0.61; P=0.02) 
at 3 months, 0.39 (IQR, 0.30–0.52; P=0.006) at 6 months, 
0.39 (IQR, 0.30–0.69; P=0.14) at 9 months, and 0.39 (IQR, 
0.30–0.76; P=0.62) at 12 months. Compared with baseline, 
the logMAR BCVA value was significantly improved at 
6 months, during the period of VPA treatment (Figure 2A).
The median MD values of VF were 28.89 dB (IQR, 
20.26–33.18) at baseline, 27.54 dB (IQR, 18.92–32.52; 
P=0.001) at 1 month, 28.14 dB (IQR, 18.29–32.60; P=0.004) 
at 3 months, 28.16 dB (IQR,18.59–31.96; P=0.004) at 
6 months, 27.97 dB (IQR, 19.51–33.11; P=0.88) at 9 months, 
and 29.15 dB (IQR, 18.68–33.06; P=0.97) at 12 months. 
Compared with baseline, the median MD values of VF were 
significantly improved at 1 month, 3 months, and 6 months, 
corresponding to the period of VPA treatment (Figure 2B).
The mean blood concentration of VPA increased to 
43.04±16.96 μg/mL at 1 month after intake. During the internal 
use period, the blood concentration of VPA was stable in each 
patient and the total mean blood concentration value of VPA 
within 6 months was 39.00±12.47 μg/mL. As shown in Figure 3, 
there were no significant relations between the mean blood VPA 
concentration values of each patient and the changes in BCVA 
(r=−0.06, P=0.73) and VF (r=−0.18, P=0.33) at 6 months.
The patients’ subjective visual symptoms reported during 
and after VPA treatment are summarized in Table 2. During 
intake of VPA, eleven of 29 (38%) patients felt no change 
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Efficacy and safety of valproic acid for retinitis pigmentosa
four (14%) patients felt legibleness, and four (14%) patients 
felt brightness. Two patients complained of blurred vision, 
but it disappeared without treatment. After the cessation of 
VPA intake, eight (28%) patients reported having blurred 
vision, four (14%) patients reported seeing dimness, three 
(10%) patients reported having photophobia, two (7%) 
patients reported difficulty seeing colors, and one (3%) 
patient experienced fatigue.
Although not included in the study design and statisti-


























Figure 1 The changes in the visual function during the Vpa administration period and the cessation period.
Notes: Box and whisker plot show changes in BCVa (A) and VF (B) during the Vpa administration period (from baseline to 6 months) and the cessation period (from 
6 months to 12 months). VFs were measured with the HFa central 10-2 program. Box edges (hinges) represent the upper and lower quartiles with the median value shown 
in the middle of the box. The whiskers extended from the hinges to the highest or lowest value are within 1.5 IQR or distance between the first and third quartiles. Data 
beyond the end of the whiskers are outliers and plotted as points. *P0.01.
Abbreviations: VPA, valproic acid; BCVA, best-corrected visual acuity; VF, visual field; HFA, Humphrey visual field analyzer; IQR, interquartile range; logMAR, logarithm 
of the minimum angle of resolution.
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Figure 2 The shift of visual function throughout the entire study.
Notes: Histograms show the shift of BCVa (A) and VF (B) throughout the entire study at months 1, 3, 6 (end of supplementation), 9, and 12. VFs were measured with the 
HFa central 10-2 program. *P0.01 and **P0.002.
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on some patients, and the preliminary results are shown in 
the Supplementary materials section. Some patients gained 
sensitivity by MP-1 at 6 months after VPA treatment 
(Figure S1). With multifocal ERG, the amplitudes of (P1-N1) 
in rings 3 and 4 (perifoveal area)16 were relatively unchanged 
between the two periods, whereas (P1-N1) amplitudes of 
ring 1 (center of the fovea) seem to increase in some patients 
after 6 months of treatment, whereas the changes after VPA 
cessation seem to be insignificant (Figure S2).
Throughout the study period, no systemic drug-related 
serious adverse events were observed in the study partici-
pants; checked blood counts from collected blood samples 
and clinical biochemistry were within normal lesion. During 
the period of VPA intake, dizziness was reported in four 
(14%) patients. Stomatitis, alopecia, and diarrhea were each 
reported in one (3%) patient.
Discussion
While several reports showed that oral VPA treatment 
improved VAs and VFs of RP patients, the opposite results 
were shown in other reports. The results of existing reports 
in VPA treatment are summarized in Table 3.
In the present study of RP patients, the BCVA and MD 
values in the HFA 10-2 program significantly improved on 
average after 6 months of VPA intake and returned to the 
baseline levels after the cessation of the VPA treatment 
(Figure 2). Based on a large cohort study of natural courses 
of RP, the mean annual rates of decline of remaining BCVA 
and VF were estimated to be 1.0%–8.6% and 2.6%–13.5%, 
respectively.17 Compared to these data, our results showed 
some beneficial effect of VPA on RP patients at the 12-month 
time point even with its confined periodic effect. We can-
not deny the possibility of placebo effect, but two previous 
studies using docosahexaenoic acid or 9-cis β-carotene had 
a randomized placebo treatment group without provision 
of multivitamin, and the placebo group in both of these 
studies worsened in VF by 1.4±1.32 dB with HFA between 
years 0 and 4 or by 0.5±4.5 cm2 with Goldmann perimetry 
within 90 days.18,19 Indeed, we cannot make a direct com-
parison between our results and these past studies, but we 
think that the VPA effect observed here is worthy of further 
investigation with a controlled study design in the future.
Nevertheless, the effect of VPA on BCVA observed in 
our study may not seem to be remarkable as one might expect 
(0.2 log units). A large cohort study showing the significant 
effect to slow the progression of RP by nutritional supple-
ments such as vitamin and docosahexaenoic acid presented 








































Figure 3 relation between the mean blood Vpa concentrations and the changes in visual functions.
Notes: Scatter plots show the relationship between mean blood Vpa concentrations and the changes in BCVa (A) and VF (B) after 6 months of Vpa treatment. VFs were 
measured with the HFa central 10-2 program.
Abbreviations: VPA, valproic acid; BCVA, best-corrected visual acuity; VF, visual field; HFA, Humphrey visual field analyzer; logMAR, logarithm of the minimum angle of 
resolution.
Table 2 patients’ subjective visual symptoms
Subjective visual  
symptoms
Number of  
patients (N=29)
During Vpa treatment, n (%)
no change 11 (38)
Clearer color vision 8 (28)
legibleness 4 (14)
Brightness 4 (14)
Blurred vision (temporal) 2 (7)
after Vpa treatment, n (%)
no change 11 (38)
Blurred vision 8 (28)
Dimness 4 (14)
photophobia 3 (10)
Difficulty to see colors 2 (7)
Fatigue 1 (3)
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Efficacy and safety of valproic acid for retinitis pigmentosa
Altogether, these results indicate that the change in BCVA 
may not be sufficiently sensitive to evaluate the efficacy of 
a treatment for RP patients. We also performed MP-1 and, 
more objectively, multifocal ERGs on a limited number 
of patients. Although the data collection was performed in 
the limited number of patients, we observed the increased 
P1-N1 amplitudes specifically in ring 1 central fovea in 
some patients after 6 months of VPA treatment. This may 
imply the effect of VPA on the area of remaining photo-
receptors, but the overall amplitudes were very small. We 
need more data to objectively evaluate the effect of VPA 
on foveal function.
In this study, there were no significant relationship 
between the mean blood VPA concentrations of each patient 
and the changes in BCVA and VF. First of all, VPA dosage 
used in this study was relatively low in order to minimize 
adverse effect of VPA, and the plasma VPA levels in our 
patients were below the therapeutic range (45–100 mg/L). 
With this low concentration, albumin binding sites on VPA 
were unsaturated, and therefore, VPA binds to albumin 
at variable degrees, making its pharmacological behavior 
difficult to estimate.22–24 If we use the therapeutic range of 
VPA, it might be able to show clearer effect of VPA on 
BCVA or VF.
We also observed a significant improvement in MD values 
of HFA 10-2 programs with VPA treatment. In the original 
report by Clemson et al, their studies were based on an in 
vitro experiment that VPA acts as a molecular chaperone of 
rhodopsin proteins that increases the yield of properly folded 
mutant rhodopsins. Therefore, these authors suggested a 
potential effect of VPA on autosomal dominant RP, targeting 
improperly folded mutant rhodopsins, in rod photoreceptors. 
Our current study included RP patients with seemingly 
various causal genes with 13 sporadic, eleven autosomal 
recessive, and five autosomal dominant hereditary patterns. 
Our HFA examination with central 10-2 program may also 
represent cone photoreceptor functions. Additionally, close 
hearing of patient’s subjective symptoms also suggested 
some improvement in cone photoreceptor function: 16 of 29 
(55%) patients felt it was easier to see during the period of 
VPA intake, whereas after cessation, eye discomfort was 
registered in 18 of 29 (62%) patients and half of the patients 
made some description related to color vision. Stasheff 
et al25,26 found that after degeneration started, ganglion cells 
exhibited hyperactivity, firing spontaneously at rates many 
times greater than normal in rd1 and rd10 mice, strains with 
closely related RP. Because the pharmacological basis of the 
antiepileptic action of VPA has been related to reduction in 
neuronal excitability by the increase in GABAergic activity, 
it is possible that VPA reduced hyperactivity of ganglion 
cells. Kimura et al27 also reported that VPA reduced retinal 
ganglion cell death in a mouse model of normal tension 
glaucoma. In this report, they indicated that VPA exerts neu-
roprotective effects through suppression of oxidative stress 
and stimulation of cell survival signaling. Therefore, patients 
may have felt that it was easier to see with reduced visual 
“noise” from spontaneous firing of ganglion cells or with 
neuroprotective effects. This phenomenon may also explain 
why BCVA and VF were improved in our study with vari-
ous types of genetic patterns. However, this hypothesis was 
based on subjective symptoms of VPA-treated RP patients, 
and we need further objective evaluation of cone-related 
functions, including color vision or contrast sensitivity, in 
VPA-treated patients.

















Clemson et al4 retrospective 7 36 (16–56) 4 (2–6) 643 (500–750) −0.172 VF (Gp) improved by 
23.5%±46.8%
Sisk7 prospective 3 11.7 (8.2–34.6) 5 (4–5) 10 mg/kg/d +0.52
Shanmugam et al9 prospective 10 42.5 (22–67) 3 (3–8) 500 −0.047 VF (HFa: program 30-2) 
improved in nine eyes
5 38.6 (14–62) 9.8 550 (500–750) na
Bhalla et al8 retrospective 21 na 14.9 na +0.056 VF (Gp) decreased by 
26.478%
Kumar et al10 prospective 15 30.4 (15–47) 12 500 −0.5 amplitude/latency 
improved in mferG/Ver
present study prospective 29 52.5 (30–72) 6 400 −0.00 VF (HFa program 10-2) 
improved by 0.73 dB
Abbreviations: VPA, valproic acid; RP, retinitis pigmentosa; BCVA, best-corrected visual acuity; logMAR, logarithm of the minimum angle of resolution; VF, visual field; 
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VPA has been widely used as an antiepileptic drug for 
several decades, and the use of VPA monotherapy in the 
treatment of epilepsy was not associated with VF defects.28,29 
However, abnormal color visions in epileptic adolescents 
treated with VPA were reported.30,31 Sisk7 reported three 
cases with complications of VPA treatment, two of which 
had severe decrease in BCVA; the two patients were 8 years 
and 15 years of age and received 10 mg/kg/d of VPA for 
4–5 months. Bhalla et al8 reported that 12 (39%) of 31 VPA-
treated patients reported systemic side effects, of whom 
nine (29%) discontinued VPA intake due to side effects. 
In this study, we did not observe a severe decline in visual 
functions or systemic adverse events to discontinue VPA 
treatment. One possible explanation is that our patients 
were all at the age of 30 years or older and the dosage of 
VPA was relatively low (400 mg/d). It is still necessary to 
carefully observe the patients’ systemic conditions during 
VPA treatment and to exercise caution when using VPA for 
young RP patients.
Conclusion
In this prospective study, we found the following: 1) while in 
use, oral intake of VPA was suggestive of a short-term benefit 
to patients with RP and 2) regardless of the genotype, there 
were no systemic drug-related adverse events. It is necessary 
to examine the effect of a longer VPA supplementation in a 
controlled study design.
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Figure S1 The changes in the retinal sensitivity during the Vpa administration period and the cessation period.
Notes: Scatter plots show changes in retinal sensitivity during the Vpa administration period (from baseline to 6 months; n=24) (A) and the cessation period (from 6 months 
to 12 months; n=24) (B). retinal sensitivities of the central 2° were measured with Mp-1.
Abbreviations: Vpa, valproic acid; Mp-1, microperimetry-1.














































Figure S2 The changes in the (p1-n1) amplitude during the Vpa administration period and the cessation period.
Notes: Scatter plots showing changes in retinal sensitivities during the Vpa administration period (from baseline to 6 months; n=21) (A) and the cessation period (from 
6 months to 12 months; n=9) (B). Multifocal erGs of the central 20° were measured with VeriS (electro-Diagnostics, inc.,) and le-4000 (Tomey).
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